REV

EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or "the Company")
today announced that the Saskatchewan Research Council ("SRC") has demonstrated
positive results in a set of viability and shelf-life tests designed to measure
the potential benefits of EnWave's freezeREV(TM) Radiant Energy Vacuum ("REV")
dehydration technology over the standard industry method for preserving
pharmaceuticals in-vial, freeze drying. Conducted at the SRC Fermentation Pilot
Plant in Saskatoon, Saskatchewan, on a live Escherichia coli ("E.coli") animal
vaccine, the tests showed that the freezeREV(TM) single-vial prototype is
capable of drying this vaccine in 50 minutes compared to 40 hours of freeze
drying, with the same bacterial survival rates.


Following the successful dehydration test, samples were then placed into a six
month shelf-life study at three different temperatures 4 degrees C, 22 degrees C
and 37 degrees C (39.2 degrees F, 71.6 degrees F and 98.6 degrees F) to measure
organism survival over time. Results from the study have shown that the
freezeREV(TM) process is comparable to freeze drying, although survival rates
were lower with the freezeREV(TM) samples stored at the highest temperature.
Scientists from both SRC and EnWave believe that this result can be improved by
making adjustments to the design of the technology, and the two companies have
now signed a Testing Agreement ("the Agreement") to collaborate on the further
development and testing of EnWave's recently announced multi-vial freezeREV(TM)
prototype.


"SRC is very pleased with these results as they show promise for the
pharmaceutical industry that so clearly needs to improve the speed and
effectiveness of its current method of preserving vaccines for shipment and
storage," said Dale Kelly, Vice-President of SRC's Agriculture, Biotechnology
and Food Division. "EnWave's freezeREV(TM) is an excellent example of Canadian
ingenuity and innovation at work, and our organization is keen to move to the
next step with EnWave in developing this exciting technology."


"Over the past three years, freezeREV(TM) has shown a great deal of promise as a
high-speed dehydration method for a wide variety of biomaterials in vials
including bacteria, enzymes, antibodies and viruses," said Dr. Tim Durance,
EnWave's Chairman and Co-CEO. "I am very much looking forward to the next stage
of development for this technology, and to continuing our productive and
cost-effective relationship with SRC."


EnWave's proprietary Radiant Energy Vacuum ("REV") technology combines microwave
energy with vacuum pressure to produce high-speed dehydration of live or active
pharmaceuticals and other biomaterials stored in vials. The Company has
developed two versions of REV for this sector: bioREV(TM), a dehydration method
for materials which require a gentler drying process without extreme temperature
changes or freezing, and freezeREV(TM), an accelerated freeze drying method for
material where low moisture levels in the final product are imperative for long
product shelf-life.


About SRC

SRC is Saskatchewan's leading provider of applied R&D and technology
commercialization. It takes the leading-edge knowledge developed in Saskatchewan
and sells it to the world and, at the same time, brings the best knowledge the
world has to offer and applies it to unique Saskatchewan situations. SRC, a
Treasury Board Crown Corporation, was established in 1947 to advance the
development of the province in the physical sciences. Today, SRC has evolved to
become a market-driven corporation, selling sevices and products to companies in
Saskatchewan and around the world. The company currently has more than 400
employees. Annual revenues are over $42.6 million and growing. More information
is available about SRC at www.src.sk.ca.


About EnWave

Using proprietary technologies developed in conjunction with the University of
British Columbia, EnWave is commercializing a new method for dehydrating food
and biological materials using Radiant Energy Vacuum ("REV") technology under
its nutraREV(TM), powderREV(TM), bioREV(TM) and freezeREV(TM) brands. REV
technology combines microwave energy transfer under vacuum to dehydrate and
alter structures and drive chemical reactions, thereby creating unique product
characteristics for both food products and medical applications that include
fruit, vegetables, probiotics, enzymes, proteins, food cultures, vaccines and
antibodies. More information about EnWave is available at www.enwave.net.


EnWave Corporation

John McNicol, President & Co-CEO

Safe Harbour for Forward-Looking Information Statements: This press release may
contain forward-looking information based on management's expectations,
estimates and projections. All statements that address expectations or
projections about the future, including statements about the Company's strategy
for growth, product development, market position, expected expenditures and
financial results are forward-looking statements. These statements are not a
guarantee of future performance and involve a number of risks, uncertainties and
assumptions. There is no guarantee that transactions contemplated under the
agreements for the acquisition of the Intellectual Property will close, there is
no guarantee the Company's REV technology can or will improve processes in the
target industry; even if the Company's REV technology can be used as described
in this document, there is no guarantee that such use will result in orders for
the Company's REV technology. All figures comparing REV technologies to freeze
drying or other dehydration technologies are provided as examples of data
obtained through the Company's own scientific and testing programs; each product
must be tested individually to determine the benefits of using REV.

(TSXV:REV)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

(TSXV:REV)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024